The HER2-specific tyrosine kinase inhibitor zongertinib was well tolerated and demonstrated promising efficacy in patients with HER2 mutation-positive non-small cell lung cancer, meeting the primary endpoint of the Beamion LUNG-1 Phase Ib Cohort 1 study, according to research presented today at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer.
World’s first rigid endoscope system for hyperspectral imaging during medical procedures
Hyperspectral imaging (HSI) is a state-of-the-art technique that captures and processes information across a given electromagnetic spectrum.
April 29, 2024